Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential of Aleglitazar to Reduce the Risk of End Stage Renal Disease and Cardiovascular Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease (Alerenal Study)

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential of Aleglitazar to Reduce the Risk of End Stage Renal Disease and Cardiovascular Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease (Alerenal Study)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aleglitazar (Primary)
  • Indications Cardiovascular disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ALERENAL
  • Sponsors Roche

    • Most Recent Events

    • 10 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment, according to a Roche media release.
    • 10 Jul 2013 New trial record
    • 09 Jul 2013 Planned number of patients changed from 5200 to 5100 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top